Our group and others have shown breast cancers, that overexpress GRP78 in response to chemotherapies, exhibit resistance to said chemotherapies [35,42,43,44], resistance to anti-estrogen therapies [13,45], and increased tumor anti-immunity [35,36]. This evidence concerns the gene HSPA5 and breast carcinoma.